How big is Aspira Women's Health, Inc.?

As of Jun 18, Aspira Women's Health, Inc. has a market capitalization of 3.65 million, with net sales of 9.31 million and a net profit of -10.32 million over the latest four quarters. Shareholder's funds are -2.56 million, and total assets amount to 5.49 million.

As of Jun 18, Aspira Women's Health, Inc. has a market capitalization of 3.65 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 9.31 million, while the sum of net profit for the same period is -10.32 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of -2.56 million and total assets amounting to 5.49 million.

What does Aspira Women's Health, Inc. do?

Aspira Women's Health, Inc. develops and commercializes diagnostic tests for gynecologic diseases, particularly ovarian cancer. As of March 2025, it reported net sales of $2 million and a net loss of $2 million, with a market cap of $3.65 million.

Overview:<BR>Aspira Women's Health, Inc. is engaged in developing and commercializing diagnostic tests for gynecologic disease, specifically focusing on ovarian cancer, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 3.65 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.41<BR>- Return on Equity: 1,130.60%<BR>- Price to Book: -3.65<BR><BR>Contact Details:<BR>- Address: Suite 100, 12117 Bee Caves Road Building Three AUSTIN TX : 78738<BR>- Tel: 1 512 5190400<BR>- Website: http://www.vermillion.com

Should I buy, sell or hold Aspira Women's Health, Inc.?

Who are in the management team of Aspira Women's Health, Inc.?

As of March 2022, the management team of Aspira Women's Health, Inc. includes Independent Chairman Mr. James LaFrance, President and CEO Ms. Valerie Palmieri, and Independent Directors Dr. Sandra Brooks, Ms. Nancy Cocozza, Dr. Veronica Jordan, and Mr. David Schreiber. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Aspira Women's Health, Inc. includes the following individuals:<BR><BR>- Mr. James LaFrance, who serves as the Independent Chairman of the Board.<BR>- Ms. Valerie Palmieri, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Sandra Brooks, who is an Independent Director.<BR>- Ms. Nancy Cocozza, who is also an Independent Director.<BR>- Dr. Veronica Jordan, who serves as an Independent Director.<BR>- Mr. David Schreiber, who is another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Is Aspira Women's Health, Inc. technically bullish or bearish?

As of September 5, 2025, Aspira Women's Health, Inc. shows a neutral technical trend with mixed signals, including bullish weekly MACD and daily moving averages, but has underperformed the S&P 500 significantly, suggesting a cautious investment approach.

As of 5 September 2025, the technical trend for Aspira Women's Health, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the Bollinger Bands show a mildly bullish weekly trend but a mildly bearish monthly trend. Daily moving averages are bullish, but the KST indicates a bearish monthly trend. The Dow Theory reflects a mildly bullish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -39.01% compared to the S&P's 12.22%, and a one-year return of -47.56% versus 17.14%. Overall, the mixed signals suggest a cautious approach.